Alveofact 108mg/ml Powder for Suspension (Each vail contains Alveofact 108mg/ml / 1 Prefilled syringe with 2.4 ml solvent)
Alveofact
What it does
Alveofact is used to help newborns with breathing difficulties, especially those born prematurely.
Commonly used for: breathing problems in newborns, respiratory distress syndrome (RDS)
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.
Sourcing - Kenya onlyRegistration & product details
Source: Food and Drugs Authority · fetched 2026-05-22 02:35:08 · updated 2026-10-30 04:00:14
About this medicine
Alveofact is used to help newborns with breathing difficulties, especially those born prematurely.
What it treats
- breathing problems in newborns
- respiratory distress syndrome (RDS)
How it works
It helps to improve the function of the lungs by increasing the amount of a substance that keeps the air sacs in the lungs open.
Who it's for
It is primarily for premature babies or those with lung problems at birth.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: alveofact
Alveofact is a medication primarily used as a surfactant replacement therapy in neonates with respiratory distress syndrome (RDS). It is derived from animal lung extracts and works to reduce surface tension in the alveoli, thereby aiding in respiratory function. By enhancing lung stability and compliance, Alveofact plays a crucial role in the management of preterm infants who are at risk of developing RDS due to surfactant deficiency.
Indications
- Respiratory distress syndrome in preterm neonates
- Prevention of RDS in at-risk neonates
Dosage
Children: Refer to the BNF for Children for specific dosing guidelines.
Mechanism of action
Alveofact contains natural surfactant proteins and lipids that mimic the action of endogenous surfactant, reducing surface tension at the air-liquid interface within the alveoli. This action prevents alveolar collapse, thereby improving gas exchange and reducing the work of breathing. The surfactant proteins also have roles in modulating inflammatory responses in the lung.
Pharmacodynamics
The pharmacodynamic properties of Alveofact include its ability to rapidly reduce surface tension in the lungs, leading to improved lung function and oxygenation. The surfactant enhances lung compliance and decreases the risk of atelectasis (lung collapse). The clinical effects of Alveofact can lead to improved outcomes in terms of oxygenation and ventilation in affected neonates.
Pharmacokinetics
Alveofact is administered intratracheally, allowing it to act directly on the lungs. Its effects are seen shortly after administration, with improvements in oxygenation and lung function. The pharmacokinetics of surfactant therapy involve distribution within the alveolar space, where it exerts its effects, and it is gradually metabolized and cleared by alveolar macrophages and epithelial cells. The duration of action is influenced by the infant's lung condition and the presence of respiratory distress.
Adverse effects
- Hypersensitivity reactions
- Fever
- Cough
- Tachycardia
- Hypotension
Precautions
- Use with caution in patients with a history of hypersensitivity to any of the components
- Monitor for adverse reactions
- Consider potential for pulmonary complications
Pregnancy
Alveofact should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, as safety in pregnancy has not been established.
Breast-feeding
Caution is advised when administering Alveofact to breastfeeding women, as it is unknown whether it is excreted in human milk.
Storage
Store in a refrigerator (2°C to 8°C). Protect from light and do not freeze.
Formulations
- Inhalation suspension
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.